Teleflex (NYSE:TFX) Issues Earnings Results

Teleflex (NYSE:TFX) posted its quarterly earnings results on Thursday. The medical technology company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.28 by $0.48, FiscalAI reports. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The business had revenue of $570.33 million during the quarter, compared to analyst estimates of $559.59 million. During the same quarter in the previous year, the business posted $3.73 EPS. The company’s quarterly revenue was up 28.9% compared to the same quarter last year. Teleflex updated its FY 2026 guidance to 6.900-7.200 EPS.

Here are the key takeaways from Teleflex’s conference call:

• Second-quarter results exceeded expectations, with pro forma adjusted constant-currency revenue growth of 4.7% and adjusted EPS of $1.76, supported by strong vascular and surgical performance.
• Teleflex lowered its 2026 revenue-growth outlook to 3.5%-4.5% from 4.5%-5.5%, primarily because integration of the Vascular Intervention acquisition is taking longer than expected and is now expected to continue through the second half of the year.
• The company raised 2026 adjusted EPS guidance to $6.90-$7.20 from $6.25-$6.55, reflecting share repurchases, lower projected interest expense, and a reduced tax-rate outlook, while maintaining an adjusted operating-margin outlook of approximately 19%.
• Teleflex closed the OEM divestiture for approximately $1.5 billion in proceeds and used much of the after-tax proceeds to repay $700 million of debt; it also plans to begin an additional $250 million accelerated share repurchase and remains committed to $1 billion of buybacks and $800 million of debt reduction.
• Innovation milestones included FDA approval of EZPLAZ freeze-dried plasma and continued progress for the Freesolve resorbable magnesium scaffold, including early completion of BIOMAG-II enrollment and commencement of the U.S. pivotal BIOMAG-III trial.

Teleflex Stock Performance

Shares of Teleflex stock traded up $2.83 during midday trading on Thursday, hitting $139.61. The company had a trading volume of 1,301,231 shares, compared to its average volume of 800,740. The company has a fifty day simple moving average of $131.41 and a 200 day simple moving average of $122.20. The stock has a market cap of $6.18 billion, a price-to-earnings ratio of -6.12, a PEG ratio of 1.04 and a beta of 0.81. The company has a quick ratio of 2.03, a current ratio of 2.55 and a debt-to-equity ratio of 0.82. Teleflex has a 12-month low of $100.18 and a 12-month high of $145.00.

Teleflex Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Friday, August 14th will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Friday, August 14th. Teleflex’s dividend payout ratio (DPR) is presently -5.96%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Raymond James Financial restated an “outperform” rating and set a $150.00 target price on shares of Teleflex in a report on Friday, May 8th. Wells Fargo & Company raised their price objective on Teleflex from $130.00 to $138.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Bank of America upgraded shares of Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 target price for the company in a report on Monday, April 13th. Truist Financial restated a “hold” rating and issued a $143.00 price target (up from $135.00) on shares of Teleflex in a report on Monday, May 11th. Finally, BMO Capital Markets assumed coverage on shares of Teleflex in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $159.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $148.90.

More Teleflex News

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Q2 earnings and revenue exceeded estimates. Teleflex reported adjusted diluted EPS of $1.76, well above the $1.28 consensus estimate, while revenue from continuing operations reached $570.3 million versus expectations of $559.6 million. Revenue rose 28.9% year over year, or 4.7% on a pro forma adjusted constant-currency basis. Teleflex Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Full-year EPS guidance was raised or set above consensus. Teleflex provided fiscal 2026 adjusted EPS guidance of $6.90-$7.20, compared with the $6.70 analyst consensus. Its revenue outlook of approximately $2.3 billion was broadly in line with expectations, reducing the risk of a sales shortfall. Teleflex Reports Second Quarter Results and Full-Year Outlook
• Neutral Sentiment: The OEM divestiture is reshaping Teleflex. Teleflex completed the $1.5 billion sale of its medical OEM business, now operating as INGENYX. The transaction may strengthen financial flexibility and sharpen focus on core medical technologies, although the business sale also changes the company’s revenue and earnings base. Teleflex Completes Sale of OEM Business
• Negative Sentiment: Reported GAAP profitability weakened year over year. GAAP diluted EPS from continuing operations was $0.96, down from $1.54 a year earlier, despite the adjusted EPS beat. The company also continues to report a negative net margin, which may temper the market’s reaction to the strong adjusted results. Teleflex Earnings Report

Institutional Investors Weigh In On Teleflex

Large investors have recently made changes to their positions in the stock. UMB Bank n.a. raised its stake in Teleflex by 57.1% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after acquiring an additional 113 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in shares of Teleflex in the fourth quarter valued at about $45,000. Danske Bank A S purchased a new position in shares of Teleflex in the third quarter worth about $54,000. State of Wyoming purchased a new position in shares of Teleflex in the second quarter worth about $111,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Teleflex by 108.1% during the second quarter. EverSource Wealth Advisors LLC now owns 1,003 shares of the medical technology company’s stock worth $119,000 after purchasing an additional 521 shares during the period. 95.62% of the stock is owned by hedge funds and other institutional investors.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.